DE60322359D1 - Imidazopyridinderivate als kinaseinhibitoren - Google Patents

Imidazopyridinderivate als kinaseinhibitoren

Info

Publication number
DE60322359D1
DE60322359D1 DE60322359T DE60322359T DE60322359D1 DE 60322359 D1 DE60322359 D1 DE 60322359D1 DE 60322359 T DE60322359 T DE 60322359T DE 60322359 T DE60322359 T DE 60322359T DE 60322359 D1 DE60322359 D1 DE 60322359D1
Authority
DE
Germany
Prior art keywords
sub
group selected
kinase inhibitors
imidazopyridine derivatives
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322359T
Other languages
English (en)
Inventor
Nicholas Bailey
Mark James Bamford
Stephen Garland
Krista B Goodman
Cui Haifeng
Mark A Hilfiker
Dennis Lee
Terence Aaron Panchal
Robert A Stavenger
David Matthew Wilson
Jason Witherington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60322359D1 publication Critical patent/DE60322359D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60322359T 2002-03-22 2003-03-21 Imidazopyridinderivate als kinaseinhibitoren Expired - Lifetime DE60322359D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206860.9A GB0206860D0 (en) 2002-03-22 2002-03-22 Compounds
PCT/GB2003/001205 WO2003080610A1 (en) 2002-03-22 2003-03-21 Imidazopyridine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60322359D1 true DE60322359D1 (de) 2008-09-04

Family

ID=9933560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322359T Expired - Lifetime DE60322359D1 (de) 2002-03-22 2003-03-21 Imidazopyridinderivate als kinaseinhibitoren

Country Status (9)

Country Link
US (1) US7348339B2 (de)
EP (1) EP1490367B1 (de)
JP (1) JP2005526802A (de)
AT (1) ATE402174T1 (de)
AU (1) AU2003215753A1 (de)
DE (1) DE60322359D1 (de)
ES (1) ES2309330T3 (de)
GB (1) GB0206860D0 (de)
WO (1) WO2003080610A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1542997T3 (da) * 2002-07-24 2012-06-25 Dermira Canada Inc Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
WO2004084813A2 (en) * 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
JP4692281B2 (ja) * 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
WO2005037198A2 (en) * 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
US7547779B2 (en) 2003-10-06 2009-06-16 Glaxo Group Limited Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
JP2007507549A (ja) * 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，６，７−三置換アザベンゾイミダゾールの調製
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
ATE512146T1 (de) * 2004-10-13 2011-06-15 Merck Patent Gmbh Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
EP2316835A1 (de) * 2004-11-22 2011-05-04 Vertex Pharmceuticals Incorporated Pyrrolopyrazine und Pyrazolopyrazine verwendbar als Inhibitoren von Proteinkinasen
JP2008526895A (ja) * 2005-01-21 2008-07-24 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なイミダゾールおよびベンゾイミダゾール誘導体
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
PE20061378A1 (es) * 2005-04-20 2006-12-03 Smithkline Beecham Corp INHIBIDORES DE LA ACTIVIDAD DE Akt
GB0512844D0 (en) * 2005-06-23 2005-08-03 Novartis Ag Organic compounds
US20090215857A1 (en) * 2005-09-13 2009-08-27 Pfizer Products Inc. Therapeutic Pyrrolidines
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
JP4738419B2 (ja) * 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
JP2009521494A (ja) * 2005-12-22 2009-06-04 アルコン リサーチ， リミテッド ｒｈｏキナーゼ媒介性疾患および状態を治療するための（インダゾール−５−イル）−ピラジンおよび（１，３−ジヒドロインドール−２−オン）−ピラジン
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2995619B1 (de) * 2006-08-02 2019-09-25 Cytokinetics, Inc. Bestimmte chemische stoffe enthaltend imidazopyrimidine, zusammensetzungen und verfahren
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
EA201001224A1 (ru) * 2008-02-04 2011-08-30 Цитокинетикс, Инкорпорейтед Химические соединения, композиции и способы их использования
EP2286232B1 (de) * 2008-05-16 2012-02-29 Cellzome Ag Verfahren zur identifizierung von mit parp wechselwirkenden molekülen und zur aufreinigung von parp-proteinen
RU2011123647A (ru) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы
SG10201607592PA (en) 2008-12-19 2016-11-29 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
EP2387315B1 (de) 2009-01-16 2015-07-15 Merck Sharp & Dohme Corp. Imidazo-[1,2-a-]pyridine und imidazo-[1,2-b-]pyridazine als mark-hemmer
PE20120003A1 (es) * 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
WO2010096746A1 (en) 2009-02-20 2010-08-26 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
CN102388130B (zh) * 2009-02-27 2014-08-27 细胞动力国际有限公司 多能细胞的分化
WO2011034741A1 (en) * 2009-09-15 2011-03-24 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
SG181947A1 (en) 2009-12-30 2012-07-30 Arqule Inc Substituted imidazopyridinyl-aminopyridine compounds
EP2569289A1 (de) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazine als hemmer der atr-kinase
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
MX2012013082A (es) 2010-05-12 2013-05-09 Vertex Pharma Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
CA2798763A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2803802A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
EP2638149B1 (de) 2010-11-12 2019-05-15 Georgetown University Immortalisierung von epithelzellen und verwendungsverfahren dafür
KR20140027974A (ko) 2011-04-05 2014-03-07 버텍스 파마슈티칼스 인코포레이티드 Ｔｒａ 키나제의 억제제로서 유용한 아미노피라진 화합물
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
CA2837727C (en) 2011-06-24 2019-12-03 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
CN102295594B (zh) * 2011-07-12 2016-01-20 上海医药工业研究院 4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
WO2013049859A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
EP2940017B1 (de) 2011-09-30 2019-08-28 Vertex Pharmaceuticals Incorporated Verfahren zur Herstellung von als Hemmer der ATR-Kinase nützlichen Verbindungen
EP2751099B1 (de) 2011-09-30 2017-06-14 Vertex Pharmaceuticals Incorporated Als art-kinasehemmer nützliche verbindungen
EP2751088B1 (de) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Als atr-kinasehemmer nützliche verbindungen
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776422A1 (de) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Als atr-kinasehemmer nützliche verbindungen
EP2776420A1 (de) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazinverbindungen als atr-kinaseinhibitoren
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
AU2013251785B2 (en) 2012-04-24 2018-05-10 Dan S. Kaufman Method for developing natural killer cells from stem cells
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
US9226922B2 (en) 2012-09-28 2016-01-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (de) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Als atr-kinaseinhibitoren nützliche verbindungen
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
TR201911151T4 (tr) 2013-03-14 2019-08-21 Tolero Pharmaceuticals Inc Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
WO2014153230A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
AU2014267360B2 (en) 2013-05-14 2018-07-05 Active Biotech Ab N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
CN111499627A (zh) * 2014-04-22 2020-08-07 艾科尔公司 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
RS60013B1 (sr) 2014-06-05 2020-04-30 Vertex Pharma Radioaktivno obeleženi derivati jedinjenja 2-amino-6-fluoro-n-[5-fluoropiridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida, korisnog kao inhibitora atr kinaze, dobijanje pomenutog jedinjenja i njegovi različiti čvrsti oblici
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
JP2017522016A (ja) 2014-06-27 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 培養哺乳動物輪部幹細胞、その産生方法及びその使用
AU2015353853B2 (en) 2014-11-25 2020-10-15 President And Fellows Of Harvard College Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
CN107636149A (zh) 2015-04-03 2018-01-26 普罗帕格尼克斯公司 上皮细胞的离体增殖
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3892718A1 (de) 2015-09-11 2021-10-13 Propagenix Inc. Ex-vivo-proliferation von epithelzellen
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US20180305334A1 (en) * 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US20200385406A1 (en) * 2017-12-22 2020-12-10 Southern Research Institute Substituted heterocyclic-pyridinones as hiv-1 nef-hck inhibitors
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
US20210189351A1 (en) 2018-08-20 2021-06-24 Propagenix Inc. Epithelial cell spheroids
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
EP4142879A1 (de) 2020-04-27 2023-03-08 Novartis AG Verfahren und zusammensetzungen zur augenzelltherapie
CA3235384A1 (en) 2021-10-18 2023-04-27 Takahiro Ochiya Compositions and methods of use thereof for treating liver fibrosis
EP4419120A2 (de) 2021-10-22 2024-08-28 Evia Life Sciences Inc. Verfahren zur herstellung von extrazellulären vesikeln sowie zusammensetzungen und verfahren zur verwendung davon
WO2024083237A1 (en) * 2022-10-20 2024-04-25 Impact Therapeutics (Shanghai) , Inc Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3722992A1 (de) * 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69737631T3 (de) * 1996-08-12 2011-08-18 Mitsubishi Tanabe Pharma Corp. MEDIKAMENTE ENTHALTEND Rho-KINASE INHIBITOREN
JP3720264B2 (ja) * 1998-08-17 2005-11-24 千寿製薬株式会社 緑内障予防・治療剤
JP2000063274A (ja) * 1998-08-20 2000-02-29 Yoshitomi Pharmaceut Ind Ltd 喘息抑制用吸入剤
CA2369552A1 (en) * 1999-04-22 2000-11-02 Hisashi Kai Agent for prophylaxis and treatment of angiostenosis
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001057018A1 (en) 2000-02-02 2001-08-09 Abbott Laboratories Azaazulene inhibitors of p38 map kinase and tnf-alpha
EP1270570B1 (de) * 2000-03-16 2006-05-31 Mitsubishi Pharma Corporation Amid-verbindung und deren verwendung
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
JP2007507549A (ja) * 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，６，７−三置換アザベンゾイミダゾールの調製

Also Published As

Publication number Publication date
US7348339B2 (en) 2008-03-25
ES2309330T3 (es) 2008-12-16
US20050197328A1 (en) 2005-09-08
EP1490367B1 (de) 2008-07-23
AU2003215753A1 (en) 2003-10-08
JP2005526802A (ja) 2005-09-08
ATE402174T1 (de) 2008-08-15
GB0206860D0 (en) 2002-05-01
WO2003080610A1 (en) 2003-10-02
EP1490367A1 (de) 2004-12-29

Similar Documents

Publication Publication Date Title
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
SE0202463D0 (sv) Novel compounds
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
NO20070432L (no) Pyrimidinureaderivater som kinaseinhibitorer
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20066055L (no) Pyridinderivater
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
NO20085087L (no) Nye heterocykliske forbindelser
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
FI962418A (fi) Syklisiä amidijohdannaisia neurokiniini A antagonisteina
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition